Bank Of New York Mellon Corp Adverum Biotechnologies, Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	SELL	$0.75 - $1.26 $21,573 - $36,242	-28,764 Reduced 42.07%	39,614 $29.8 Million
Q3 2023 Oct 24, 2023	SELL	$1.5 - $2.33 $1,176 - $1,826	-784 Reduced 1.13%	68,378 $103 Million
Q2 2023 Aug 03, 2023	BUY	$0.68 - $1.59 $9,980 - $23,336	14,677 Added 26.94%	69,162 $110 Million
Q1 2023 May 09, 2023	BUY	$0.62 - $0.85 $33,780 - $46,312	54,485 New	54,485 $39.1 Million
Q4 2022 Feb 14, 2023	BUY	$0.54 - $10.3 $29,421 - $561,195	54,485 New	54,485 $31,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $14,501 - $146,226	-15,106 Reduced 21.67%	54,601 $52,000
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $205,317 - $339,660	-253,478 Reduced 78.43%	69,707 $84,000
Q1 2022 May 11, 2022	SELL	$1.23 - $1.95 $4,997 - $7,922	-4,063 Reduced 1.24%	323,185 $424,000
Q4 2021 Feb 11, 2022	BUY	$1.74 - $2.4 $8,270 - $11,407	4,753 Added 1.47%	327,248 $576,000
Q3 2021 Nov 12, 2021	BUY	$2.08 - $3.6 $34,247 - $59,274	16,465 Added 5.38%	322,495 $700,000
Q2 2021 Aug 11, 2021	SELL	$3.36 - $10.56 $55,413 - $174,155	-16,492 Reduced 5.11%	306,030 $1.07 Million
Q1 2021 May 13, 2021	SELL	$9.26 - $14.36 $142,770 - $221,402	-15,418 Reduced 4.56%	322,522 $3.18 Million
Q4 2020 Feb 09, 2021	BUY	$9.84 - $14.26 $57,632 - $83,520	5,857 Added 1.76%	337,940 $3.66 Million
Q3 2020 Nov 12, 2020	BUY	$10.3 - $21.64 $44,393 - $93,268	4,310 Added 1.31%	332,083 $3.42 Million
Q2 2020 Aug 12, 2020	BUY	$8.53 - $25.64 $589,201 - $1.77 Million	69,074 Added 26.7%	327,773 $6.84 Million
Q1 2020 May 06, 2020	BUY	$7.98 - $16.32 $159,711 - $326,628	20,014 Added 8.39%	258,699 $2.53 Million
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $236,963 - $565,566	46,282 Added 24.05%	238,685 $2.75 Million
Q3 2019 Nov 07, 2019	SELL	$5.24 - $15.89 $355,240 - $1.08 Million	-67,794 Reduced 26.05%	192,403 $1.05 Million
Q2 2019 Aug 12, 2019	BUY	$5.1 - $11.89 $216,066 - $503,731	42,366 Added 19.45%	260,197 $3.09 Million
Q1 2019 May 14, 2019	SELL	$3.03 - $6.02 $236 - $469	-78 Reduced 0.04%	217,831 $1.14 Million
Q4 2018 Feb 11, 2019	SELL	$2.87 - $5.92 $5,381 - $11,100	-1,875 Reduced 0.85%	217,909 $686,000
Q3 2018 Nov 09, 2018	BUY	$4.5 - $7.6 $149,332 - $252,206	33,185 Added 17.78%	219,784 $0
Q2 2018 Aug 06, 2018	BUY	$5.3 - $6.9 $713,957 - $929,492	134,709 Added 259.6%	186,599 $989,000
Q1 2018 May 15, 2018	BUY	$3.65 - $7.95 $40,168 - $87,489	11,005 Added 26.92%	51,890 $301,000
Q4 2017 Feb 09, 2018	BUY	$2.85 - $3.95 $116,522 - $161,495	40,885	40,885 $143,000

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$2.4 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$74,418
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$5,451
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account